Company intelligence / Profile preview

CERo Therapeutics

South San Francisco, California, United Statescero.bio ↗

Ownership: Private
Employees: ~9
Development stage: Other

01

Overview

Positive FDA review of CMC amendment for AML trial (March'2025)[4]
Second IND clearance for solid tumors (March'2025)[5]
Preclinical data showing ovarian cancer cytotoxicity without toxicity (Nov'2024)[6]

Therapeutic areas: OncologyHematology
Modalities: Engineered T cell therapeuticsCell therapy
Industry: Biotech

02

Drug pipeline

1 asset

CER-1236

1

03

Partnerships

UC Davis

Beyond the preview

Go deeper on CERo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CERo Therapeutics.

Explore the full profile